Premium
Rapid Communication Muscle Mitochondrial ATP Production in Progressive Supranuclear Palsy
Author(s) -
Monte Donate A. Di,
Harati Yadollah,
Jankovic Joseph,
Sandy Martha S.,
Jewell Sarah A.,
Langston J. William
Publication year - 1994
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1046/j.1471-4159.1994.62041631.x
Subject(s) - progressive supranuclear palsy , mitochondrion , neuroscience , production (economics) , physical medicine and rehabilitation , biology , medicine , microbiology and biotechnology , disease , macroeconomics , economics
Six patients with progressive supranuclear palsy (PSP) and 12 age‐matched disease‐free subjects participated in this study designed to compare rates of ATP production by intact mitochondria from biopsied skeletal muscle. When pyruvate and malate were used as metabolic substrates, rates of ATP production were 0.184 ± 0.025 μmol/min/U of citrate synthase (CS) activity (a mitochondrial marker) in control subjects and 0.131 ± 0.051 μmol/min/U of CS in PSP patients. In the presence of succinate, rates of ATP formation were 0.137 + 0.02 μmol/min/U of CS in controls and 0.109 ± 0.04 /4mUmol/min/U of CS in patients. With N,N,N′,N′ ‐tetramethyl‐ p ‐phenylenediamine (TMPD) and ascorbate, rates were 0.034 ± 0.008 μm Umol/min/U of CS in controls and 0.022 ± 0.01 μmol/min/U of CS in PSP subjects. Differences between the control and PSP populations reached statistical significance with pyruvate/malate and TMPD/ascorbate. No differences in either muscle histopathology or histochemistry were found between patient and control subjects. Results of this study suggest that oxidative phosphorylation defects occur in muscle mitochondria from patients with PSP.